nodes	percent_of_prediction	percent_of_DWPC	metapath
Cladribine—Azacitidine—Gemcitabine—kidney cancer	0.126	0.512	CrCrCtD
Cladribine—Decitabine—Gemcitabine—kidney cancer	0.12	0.488	CrCrCtD
Cladribine—POLE—Gemcitabine—kidney cancer	0.0958	0.19	CbGbCtD
Cladribine—NR5A1—Vinblastine—kidney cancer	0.0759	0.151	CbGbCtD
Cladribine—RRM2—Gemcitabine—kidney cancer	0.0636	0.127	CbGbCtD
Cladribine—RRM1—Gemcitabine—kidney cancer	0.0636	0.127	CbGbCtD
Cladribine—POLA1—Gemcitabine—kidney cancer	0.055	0.109	CbGbCtD
Cladribine—SLC28A3—Gemcitabine—kidney cancer	0.055	0.109	CbGbCtD
Cladribine—DCK—Gemcitabine—kidney cancer	0.0339	0.0673	CbGbCtD
Cladribine—ABCG2—Pazopanib—kidney cancer	0.00998	0.0198	CbGbCtD
Cladribine—ABCG2—Dactinomycin—kidney cancer	0.00913	0.0181	CbGbCtD
Cladribine—SLC22A2—Vinblastine—kidney cancer	0.00775	0.0154	CbGbCtD
Cladribine—ABCG2—Erlotinib—kidney cancer	0.00712	0.0142	CbGbCtD
Cladribine—ABCG2—Paclitaxel—kidney cancer	0.00652	0.013	CbGbCtD
Cladribine—ABCG2—Sorafenib—kidney cancer	0.00579	0.0115	CbGbCtD
Cladribine—ABCG2—Vincristine—kidney cancer	0.00562	0.0112	CbGbCtD
Cladribine—ABCG2—Sunitinib—kidney cancer	0.00469	0.00933	CbGbCtD
Cladribine—SLC22A2—nephron—kidney cancer	0.00367	0.0919	CbGeAlD
Cladribine—ABCG2—Doxorubicin—kidney cancer	0.00351	0.00699	CbGbCtD
Cladribine—POLE4—renal system—kidney cancer	0.00303	0.0759	CbGeAlD
Cladribine—PNP—renal system—kidney cancer	0.00168	0.042	CbGeAlD
Cladribine—PNP—kidney—kidney cancer	0.00162	0.0406	CbGeAlD
Cladribine—POLE3—nephron tubule—kidney cancer	0.00162	0.0405	CbGeAlD
Cladribine—RRM2B—renal system—kidney cancer	0.00156	0.039	CbGeAlD
Cladribine—POLE3—renal system—kidney cancer	0.00147	0.0368	CbGeAlD
Cladribine—RRM2B—cortex of kidney—kidney cancer	0.00147	0.0367	CbGeAlD
Cladribine—POLE3—kidney—kidney cancer	0.00142	0.0356	CbGeAlD
Cladribine—RRM2B—cardiac atrium—kidney cancer	0.00139	0.0349	CbGeAlD
Cladribine—POLE3—cortex of kidney—kidney cancer	0.00139	0.0347	CbGeAlD
Cladribine—POLE3—gonad—kidney cancer	0.00132	0.033	CbGeAlD
Cladribine—POLE3—cardiac atrium—kidney cancer	0.00132	0.033	CbGeAlD
Cladribine—NR5A1—gonad—kidney cancer	0.00128	0.032	CbGeAlD
Cladribine—POLE—cortex of kidney—kidney cancer	0.00106	0.0265	CbGeAlD
Cladribine—POLE—gonad—kidney cancer	0.00101	0.0252	CbGeAlD
Cladribine—RRM2—renal system—kidney cancer	0.000925	0.0231	CbGeAlD
Cladribine—RRM2—kidney—kidney cancer	0.000894	0.0224	CbGeAlD
Cladribine—RRM1—nephron tubule—kidney cancer	0.000845	0.0212	CbGeAlD
Cladribine—RRM2—gonad—kidney cancer	0.000829	0.0208	CbGeAlD
Cladribine—Adenosine monophosphate—APRT—kidney cancer	0.000828	1	CrCbGaD
Cladribine—SLC22A2—nephron tubule—kidney cancer	0.000793	0.0198	CbGeAlD
Cladribine—RRM1—renal system—kidney cancer	0.000768	0.0192	CbGeAlD
Cladribine—RRM1—kidney—kidney cancer	0.000743	0.0186	CbGeAlD
Cladribine—RRM1—cortex of kidney—kidney cancer	0.000723	0.0181	CbGeAlD
Cladribine—SLC22A2—renal system—kidney cancer	0.000721	0.018	CbGeAlD
Cladribine—SLC22A2—kidney—kidney cancer	0.000697	0.0174	CbGeAlD
Cladribine—RRM1—gonad—kidney cancer	0.000689	0.0172	CbGeAlD
Cladribine—RRM1—cardiac atrium—kidney cancer	0.000688	0.0172	CbGeAlD
Cladribine—SLC22A2—cortex of kidney—kidney cancer	0.000678	0.017	CbGeAlD
Cladribine—DCK—nephron tubule—kidney cancer	0.000657	0.0164	CbGeAlD
Cladribine—DCK—cortex of kidney—kidney cancer	0.000562	0.0141	CbGeAlD
Cladribine—DCK—gonad—kidney cancer	0.000535	0.0134	CbGeAlD
Cladribine—DCK—cardiac atrium—kidney cancer	0.000535	0.0134	CbGeAlD
Cladribine—SLC22A1—renal system—kidney cancer	0.000509	0.0127	CbGeAlD
Cladribine—SLC22A1—kidney—kidney cancer	0.000492	0.0123	CbGeAlD
Cladribine—ABCG2—nephron tubule—kidney cancer	0.000366	0.00917	CbGeAlD
Cladribine—POLE2—Temsirolimus—Everolimus—kidney cancer	0.000284	0.0951	CbGdCrCtD
Cladribine—POLE2—Everolimus—Temsirolimus—kidney cancer	0.000284	0.0951	CbGdCrCtD
Cladribine—RRM2—Gefitinib—Erlotinib—kidney cancer	0.000225	0.0753	CbGdCrCtD
Cladribine—PNP—Sirolimus—Temsirolimus—kidney cancer	0.000219	0.0734	CbGdCrCtD
Cladribine—PNP—Temsirolimus—Everolimus—kidney cancer	0.000219	0.0734	CbGdCrCtD
Cladribine—PNP—Sirolimus—Everolimus—kidney cancer	0.000219	0.0734	CbGdCrCtD
Cladribine—PNP—Gefitinib—Erlotinib—kidney cancer	0.000219	0.0731	CbGdCrCtD
Cladribine—RRM2—Vinorelbine—Vincristine—kidney cancer	0.000151	0.0504	CbGdCrCtD
Cladribine—RRM2—Vinorelbine—Vinblastine—kidney cancer	0.000151	0.0504	CbGdCrCtD
Cladribine—POLA1—Vinblastine—Vincristine—kidney cancer	0.000143	0.0477	CbGdCrCtD
Cladribine—DCK—Sirolimus—Temsirolimus—kidney cancer	0.000128	0.0428	CbGdCrCtD
Cladribine—DCK—Sirolimus—Everolimus—kidney cancer	0.000128	0.0428	CbGdCrCtD
Cladribine—RRM1—Azacitidine—Gemcitabine—kidney cancer	9.67e-05	0.0324	CbGdCrCtD
Cladribine—POLE2—Idarubicin—Doxorubicin—kidney cancer	9.15e-05	0.0306	CbGdCrCtD
Cladribine—POLE2—Daunorubicin—Doxorubicin—kidney cancer	9.15e-05	0.0306	CbGdCrCtD
Cladribine—POLE2—Epirubicin—Doxorubicin—kidney cancer	9.15e-05	0.0306	CbGdCrCtD
Cladribine—POLE2—Azacitidine—Gemcitabine—kidney cancer	7.65e-05	0.0256	CbGdCrCtD
Cladribine—PNP—Daunorubicin—Doxorubicin—kidney cancer	7.06e-05	0.0236	CbGdCrCtD
Cladribine—RRM2—Azacitidine—Gemcitabine—kidney cancer	6.07e-05	0.0203	CbGdCrCtD
Cladribine—Decreased appetite—Vincristine—kidney cancer	4.57e-05	0.000334	CcSEcCtD
Cladribine—Pruritus—Sorafenib—kidney cancer	4.57e-05	0.000334	CcSEcCtD
Cladribine—Vomiting—Erlotinib—kidney cancer	4.56e-05	0.000334	CcSEcCtD
Cladribine—Erythema multiforme—Capecitabine—kidney cancer	4.56e-05	0.000333	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Gemcitabine—kidney cancer	4.54e-05	0.000332	CcSEcCtD
Cladribine—Gastrointestinal disorder—Vincristine—kidney cancer	4.54e-05	0.000332	CcSEcCtD
Cladribine—Fatigue—Vincristine—kidney cancer	4.53e-05	0.000331	CcSEcCtD
Cladribine—Rash—Erlotinib—kidney cancer	4.53e-05	0.000331	CcSEcCtD
Cladribine—Dermatitis—Erlotinib—kidney cancer	4.52e-05	0.000331	CcSEcCtD
Cladribine—Insomnia—Gemcitabine—kidney cancer	4.51e-05	0.00033	CcSEcCtD
Cladribine—Eye disorder—Capecitabine—kidney cancer	4.51e-05	0.00033	CcSEcCtD
Cladribine—Headache—Erlotinib—kidney cancer	4.5e-05	0.000329	CcSEcCtD
Cladribine—Constipation—Vincristine—kidney cancer	4.49e-05	0.000329	CcSEcCtD
Cladribine—Pain—Vincristine—kidney cancer	4.49e-05	0.000329	CcSEcCtD
Cladribine—Pain in extremity—Doxorubicin—kidney cancer	4.49e-05	0.000329	CcSEcCtD
Cladribine—Paraesthesia—Gemcitabine—kidney cancer	4.48e-05	0.000327	CcSEcCtD
Cladribine—Cardiac disorder—Capecitabine—kidney cancer	4.47e-05	0.000327	CcSEcCtD
Cladribine—Cough—Paclitaxel—kidney cancer	4.46e-05	0.000326	CcSEcCtD
Cladribine—Asthenia—Sunitinib—kidney cancer	4.46e-05	0.000326	CcSEcCtD
Cladribine—Dyspnoea—Gemcitabine—kidney cancer	4.44e-05	0.000325	CcSEcCtD
Cladribine—Nausea—Vinblastine—kidney cancer	4.44e-05	0.000324	CcSEcCtD
Cladribine—Somnolence—Gemcitabine—kidney cancer	4.43e-05	0.000324	CcSEcCtD
Cladribine—Nausea—Everolimus—kidney cancer	4.42e-05	0.000323	CcSEcCtD
Cladribine—Diarrhoea—Sorafenib—kidney cancer	4.42e-05	0.000323	CcSEcCtD
Cladribine—Pruritus—Sunitinib—kidney cancer	4.4e-05	0.000321	CcSEcCtD
Cladribine—Angiopathy—Capecitabine—kidney cancer	4.37e-05	0.00032	CcSEcCtD
Cladribine—Immune system disorder—Capecitabine—kidney cancer	4.35e-05	0.000318	CcSEcCtD
Cladribine—Myalgia—Paclitaxel—kidney cancer	4.35e-05	0.000318	CcSEcCtD
Cladribine—Arthralgia—Paclitaxel—kidney cancer	4.35e-05	0.000318	CcSEcCtD
Cladribine—Chest pain—Paclitaxel—kidney cancer	4.35e-05	0.000318	CcSEcCtD
Cladribine—Mediastinal disorder—Capecitabine—kidney cancer	4.34e-05	0.000318	CcSEcCtD
Cladribine—Anxiety—Paclitaxel—kidney cancer	4.34e-05	0.000317	CcSEcCtD
Cladribine—Decreased appetite—Gemcitabine—kidney cancer	4.33e-05	0.000317	CcSEcCtD
Cladribine—Hypersensitivity—Dactinomycin—kidney cancer	4.33e-05	0.000317	CcSEcCtD
Cladribine—Chills—Capecitabine—kidney cancer	4.33e-05	0.000316	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	4.32e-05	0.000316	CcSEcCtD
Cladribine—Arrhythmia—Capecitabine—kidney cancer	4.31e-05	0.000315	CcSEcCtD
Cladribine—Gastrointestinal disorder—Gemcitabine—kidney cancer	4.3e-05	0.000315	CcSEcCtD
Cladribine—Discomfort—Paclitaxel—kidney cancer	4.3e-05	0.000315	CcSEcCtD
Cladribine—Fatigue—Gemcitabine—kidney cancer	4.3e-05	0.000314	CcSEcCtD
Cladribine—Gastrointestinal pain—Vincristine—kidney cancer	4.3e-05	0.000314	CcSEcCtD
Cladribine—Dizziness—Sorafenib—kidney cancer	4.27e-05	0.000312	CcSEcCtD
Cladribine—Constipation—Gemcitabine—kidney cancer	4.26e-05	0.000312	CcSEcCtD
Cladribine—Pain—Gemcitabine—kidney cancer	4.26e-05	0.000312	CcSEcCtD
Cladribine—Nausea—Erlotinib—kidney cancer	4.26e-05	0.000312	CcSEcCtD
Cladribine—Alopecia—Capecitabine—kidney cancer	4.26e-05	0.000312	CcSEcCtD
Cladribine—Diarrhoea—Sunitinib—kidney cancer	4.25e-05	0.000311	CcSEcCtD
Cladribine—Ataxia—Doxorubicin—kidney cancer	4.22e-05	0.000309	CcSEcCtD
Cladribine—Mental disorder—Capecitabine—kidney cancer	4.22e-05	0.000309	CcSEcCtD
Cladribine—Asthenia—Dactinomycin—kidney cancer	4.22e-05	0.000309	CcSEcCtD
Cladribine—Confusional state—Paclitaxel—kidney cancer	4.21e-05	0.000308	CcSEcCtD
Cladribine—Erythema—Capecitabine—kidney cancer	4.2e-05	0.000307	CcSEcCtD
Cladribine—Malnutrition—Capecitabine—kidney cancer	4.2e-05	0.000307	CcSEcCtD
Cladribine—Oedema—Paclitaxel—kidney cancer	4.17e-05	0.000305	CcSEcCtD
Cladribine—Abdominal pain—Vincristine—kidney cancer	4.15e-05	0.000304	CcSEcCtD
Cladribine—Body temperature increased—Vincristine—kidney cancer	4.15e-05	0.000304	CcSEcCtD
Cladribine—Infection—Paclitaxel—kidney cancer	4.15e-05	0.000303	CcSEcCtD
Cladribine—Flatulence—Capecitabine—kidney cancer	4.14e-05	0.000302	CcSEcCtD
Cladribine—DCK—Epirubicin—Doxorubicin—kidney cancer	4.12e-05	0.0138	CbGdCrCtD
Cladribine—Dizziness—Sunitinib—kidney cancer	4.11e-05	0.0003	CcSEcCtD
Cladribine—Feeling abnormal—Gemcitabine—kidney cancer	4.11e-05	0.0003	CcSEcCtD
Cladribine—Vomiting—Sorafenib—kidney cancer	4.11e-05	0.0003	CcSEcCtD
Cladribine—Nervous system disorder—Paclitaxel—kidney cancer	4.09e-05	0.000299	CcSEcCtD
Cladribine—Thrombocytopenia—Paclitaxel—kidney cancer	4.09e-05	0.000299	CcSEcCtD
Cladribine—Tachycardia—Paclitaxel—kidney cancer	4.07e-05	0.000298	CcSEcCtD
Cladribine—Rash—Sorafenib—kidney cancer	4.07e-05	0.000298	CcSEcCtD
Cladribine—Dermatitis—Sorafenib—kidney cancer	4.07e-05	0.000297	CcSEcCtD
Cladribine—Back pain—Capecitabine—kidney cancer	4.06e-05	0.000297	CcSEcCtD
Cladribine—Skin disorder—Paclitaxel—kidney cancer	4.05e-05	0.000296	CcSEcCtD
Cladribine—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	4.05e-05	0.000296	CcSEcCtD
Cladribine—Headache—Sorafenib—kidney cancer	4.04e-05	0.000296	CcSEcCtD
Cladribine—Hyperhidrosis—Paclitaxel—kidney cancer	4.03e-05	0.000295	CcSEcCtD
Cladribine—Diarrhoea—Dactinomycin—kidney cancer	4.02e-05	0.000294	CcSEcCtD
Cladribine—Anorexia—Paclitaxel—kidney cancer	3.98e-05	0.000291	CcSEcCtD
Cladribine—Muscular weakness—Doxorubicin—kidney cancer	3.96e-05	0.00029	CcSEcCtD
Cladribine—Vomiting—Sunitinib—kidney cancer	3.95e-05	0.000289	CcSEcCtD
Cladribine—Body temperature increased—Gemcitabine—kidney cancer	3.94e-05	0.000288	CcSEcCtD
Cladribine—Rash—Sunitinib—kidney cancer	3.92e-05	0.000286	CcSEcCtD
Cladribine—Dermatitis—Sunitinib—kidney cancer	3.91e-05	0.000286	CcSEcCtD
Cladribine—Hypotension—Paclitaxel—kidney cancer	3.9e-05	0.000285	CcSEcCtD
Cladribine—Ill-defined disorder—Capecitabine—kidney cancer	3.89e-05	0.000285	CcSEcCtD
Cladribine—Headache—Sunitinib—kidney cancer	3.89e-05	0.000285	CcSEcCtD
Cladribine—Anaemia—Capecitabine—kidney cancer	3.88e-05	0.000284	CcSEcCtD
Cladribine—Hypersensitivity—Vincristine—kidney cancer	3.87e-05	0.000283	CcSEcCtD
Cladribine—Eosinophilia—Doxorubicin—kidney cancer	3.84e-05	0.000281	CcSEcCtD
Cladribine—Nausea—Sorafenib—kidney cancer	3.84e-05	0.00028	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Paclitaxel—kidney cancer	3.8e-05	0.000278	CcSEcCtD
Cladribine—Malaise—Capecitabine—kidney cancer	3.78e-05	0.000277	CcSEcCtD
Cladribine—Insomnia—Paclitaxel—kidney cancer	3.77e-05	0.000276	CcSEcCtD
Cladribine—Asthenia—Vincristine—kidney cancer	3.77e-05	0.000276	CcSEcCtD
Cladribine—Paraesthesia—Paclitaxel—kidney cancer	3.75e-05	0.000274	CcSEcCtD
Cladribine—Vomiting—Dactinomycin—kidney cancer	3.74e-05	0.000273	CcSEcCtD
Cladribine—Dyspnoea—Paclitaxel—kidney cancer	3.72e-05	0.000272	CcSEcCtD
Cladribine—Somnolence—Paclitaxel—kidney cancer	3.71e-05	0.000271	CcSEcCtD
Cladribine—Rash—Dactinomycin—kidney cancer	3.71e-05	0.000271	CcSEcCtD
Cladribine—Nausea—Sunitinib—kidney cancer	3.69e-05	0.00027	CcSEcCtD
Cladribine—Pancytopenia—Doxorubicin—kidney cancer	3.69e-05	0.00027	CcSEcCtD
Cladribine—Cough—Capecitabine—kidney cancer	3.66e-05	0.000268	CcSEcCtD
Cladribine—Neutropenia—Doxorubicin—kidney cancer	3.63e-05	0.000266	CcSEcCtD
Cladribine—Decreased appetite—Paclitaxel—kidney cancer	3.63e-05	0.000265	CcSEcCtD
Cladribine—Upper respiratory tract infection—Doxorubicin—kidney cancer	3.61e-05	0.000264	CcSEcCtD
Cladribine—Gastrointestinal disorder—Paclitaxel—kidney cancer	3.6e-05	0.000264	CcSEcCtD
Cladribine—Fatigue—Paclitaxel—kidney cancer	3.6e-05	0.000263	CcSEcCtD
Cladribine—Diarrhoea—Vincristine—kidney cancer	3.6e-05	0.000263	CcSEcCtD
Cladribine—Asthenia—Gemcitabine—kidney cancer	3.58e-05	0.000262	CcSEcCtD
Cladribine—Myalgia—Capecitabine—kidney cancer	3.57e-05	0.000261	CcSEcCtD
Cladribine—Arthralgia—Capecitabine—kidney cancer	3.57e-05	0.000261	CcSEcCtD
Cladribine—Chest pain—Capecitabine—kidney cancer	3.57e-05	0.000261	CcSEcCtD
Cladribine—Pain—Paclitaxel—kidney cancer	3.57e-05	0.000261	CcSEcCtD
Cladribine—Constipation—Paclitaxel—kidney cancer	3.57e-05	0.000261	CcSEcCtD
Cladribine—Anxiety—Capecitabine—kidney cancer	3.56e-05	0.00026	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	3.55e-05	0.00026	CcSEcCtD
Cladribine—Discomfort—Capecitabine—kidney cancer	3.53e-05	0.000258	CcSEcCtD
Cladribine—Pruritus—Gemcitabine—kidney cancer	3.53e-05	0.000258	CcSEcCtD
Cladribine—Nausea—Dactinomycin—kidney cancer	3.49e-05	0.000256	CcSEcCtD
Cladribine—Pneumonia—Doxorubicin—kidney cancer	3.48e-05	0.000255	CcSEcCtD
Cladribine—Dizziness—Vincristine—kidney cancer	3.47e-05	0.000254	CcSEcCtD
Cladribine—Infestation NOS—Doxorubicin—kidney cancer	3.46e-05	0.000253	CcSEcCtD
Cladribine—Infestation—Doxorubicin—kidney cancer	3.46e-05	0.000253	CcSEcCtD
Cladribine—Confusional state—Capecitabine—kidney cancer	3.45e-05	0.000253	CcSEcCtD
Cladribine—Feeling abnormal—Paclitaxel—kidney cancer	3.44e-05	0.000252	CcSEcCtD
Cladribine—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	3.43e-05	0.000251	CcSEcCtD
Cladribine—Oedema—Capecitabine—kidney cancer	3.43e-05	0.000251	CcSEcCtD
Cladribine—Gastrointestinal pain—Paclitaxel—kidney cancer	3.41e-05	0.00025	CcSEcCtD
Cladribine—Diarrhoea—Gemcitabine—kidney cancer	3.41e-05	0.000249	CcSEcCtD
Cladribine—Renal failure—Doxorubicin—kidney cancer	3.4e-05	0.000249	CcSEcCtD
Cladribine—Infection—Capecitabine—kidney cancer	3.4e-05	0.000249	CcSEcCtD
Cladribine—Conjunctivitis—Doxorubicin—kidney cancer	3.36e-05	0.000246	CcSEcCtD
Cladribine—Urinary tract infection—Doxorubicin—kidney cancer	3.36e-05	0.000246	CcSEcCtD
Cladribine—Nervous system disorder—Capecitabine—kidney cancer	3.36e-05	0.000246	CcSEcCtD
Cladribine—Thrombocytopenia—Capecitabine—kidney cancer	3.35e-05	0.000245	CcSEcCtD
Cladribine—Tachycardia—Capecitabine—kidney cancer	3.34e-05	0.000244	CcSEcCtD
Cladribine—Vomiting—Vincristine—kidney cancer	3.34e-05	0.000244	CcSEcCtD
Cladribine—Skin disorder—Capecitabine—kidney cancer	3.33e-05	0.000243	CcSEcCtD
Cladribine—Urticaria—Paclitaxel—kidney cancer	3.32e-05	0.000242	CcSEcCtD
Cladribine—Rash—Vincristine—kidney cancer	3.31e-05	0.000242	CcSEcCtD
Cladribine—Hyperhidrosis—Capecitabine—kidney cancer	3.31e-05	0.000242	CcSEcCtD
Cladribine—Dermatitis—Vincristine—kidney cancer	3.31e-05	0.000242	CcSEcCtD
Cladribine—Body temperature increased—Paclitaxel—kidney cancer	3.3e-05	0.000241	CcSEcCtD
Cladribine—Abdominal pain—Paclitaxel—kidney cancer	3.3e-05	0.000241	CcSEcCtD
Cladribine—Headache—Vincristine—kidney cancer	3.29e-05	0.000241	CcSEcCtD
Cladribine—Hepatobiliary disease—Doxorubicin—kidney cancer	3.27e-05	0.000239	CcSEcCtD
Cladribine—Epistaxis—Doxorubicin—kidney cancer	3.27e-05	0.000239	CcSEcCtD
Cladribine—Anorexia—Capecitabine—kidney cancer	3.26e-05	0.000239	CcSEcCtD
Cladribine—Hypotension—Capecitabine—kidney cancer	3.2e-05	0.000234	CcSEcCtD
Cladribine—Vomiting—Gemcitabine—kidney cancer	3.17e-05	0.000232	CcSEcCtD
Cladribine—Rash—Gemcitabine—kidney cancer	3.14e-05	0.00023	CcSEcCtD
Cladribine—Dermatitis—Gemcitabine—kidney cancer	3.14e-05	0.00023	CcSEcCtD
Cladribine—Haemoglobin—Doxorubicin—kidney cancer	3.12e-05	0.000228	CcSEcCtD
Cladribine—Headache—Gemcitabine—kidney cancer	3.12e-05	0.000228	CcSEcCtD
Cladribine—Nausea—Vincristine—kidney cancer	3.12e-05	0.000228	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Capecitabine—kidney cancer	3.12e-05	0.000228	CcSEcCtD
Cladribine—Haemorrhage—Doxorubicin—kidney cancer	3.11e-05	0.000227	CcSEcCtD
Cladribine—Insomnia—Capecitabine—kidney cancer	3.1e-05	0.000227	CcSEcCtD
Cladribine—Pharyngitis—Doxorubicin—kidney cancer	3.08e-05	0.000226	CcSEcCtD
Cladribine—Paraesthesia—Capecitabine—kidney cancer	3.08e-05	0.000225	CcSEcCtD
Cladribine—Hypersensitivity—Paclitaxel—kidney cancer	3.08e-05	0.000225	CcSEcCtD
Cladribine—Urinary tract disorder—Doxorubicin—kidney cancer	3.07e-05	0.000224	CcSEcCtD
Cladribine—Oedema peripheral—Doxorubicin—kidney cancer	3.06e-05	0.000224	CcSEcCtD
Cladribine—Connective tissue disorder—Doxorubicin—kidney cancer	3.05e-05	0.000223	CcSEcCtD
Cladribine—Dyspnoea—Capecitabine—kidney cancer	3.05e-05	0.000223	CcSEcCtD
Cladribine—Urethral disorder—Doxorubicin—kidney cancer	3.05e-05	0.000223	CcSEcCtD
Cladribine—Asthenia—Paclitaxel—kidney cancer	2.99e-05	0.000219	CcSEcCtD
Cladribine—Decreased appetite—Capecitabine—kidney cancer	2.98e-05	0.000218	CcSEcCtD
Cladribine—Nausea—Gemcitabine—kidney cancer	2.96e-05	0.000217	CcSEcCtD
Cladribine—Gastrointestinal disorder—Capecitabine—kidney cancer	2.96e-05	0.000216	CcSEcCtD
Cladribine—Fatigue—Capecitabine—kidney cancer	2.95e-05	0.000216	CcSEcCtD
Cladribine—Pruritus—Paclitaxel—kidney cancer	2.95e-05	0.000216	CcSEcCtD
Cladribine—Erythema multiforme—Doxorubicin—kidney cancer	2.94e-05	0.000215	CcSEcCtD
Cladribine—Pain—Capecitabine—kidney cancer	2.93e-05	0.000214	CcSEcCtD
Cladribine—Constipation—Capecitabine—kidney cancer	2.93e-05	0.000214	CcSEcCtD
Cladribine—Eye disorder—Doxorubicin—kidney cancer	2.9e-05	0.000212	CcSEcCtD
Cladribine—Cardiac disorder—Doxorubicin—kidney cancer	2.88e-05	0.000211	CcSEcCtD
Cladribine—Diarrhoea—Paclitaxel—kidney cancer	2.86e-05	0.000209	CcSEcCtD
Cladribine—Feeling abnormal—Capecitabine—kidney cancer	2.82e-05	0.000206	CcSEcCtD
Cladribine—Angiopathy—Doxorubicin—kidney cancer	2.82e-05	0.000206	CcSEcCtD
Cladribine—Immune system disorder—Doxorubicin—kidney cancer	2.81e-05	0.000205	CcSEcCtD
Cladribine—Gastrointestinal pain—Capecitabine—kidney cancer	2.8e-05	0.000205	CcSEcCtD
Cladribine—Mediastinal disorder—Doxorubicin—kidney cancer	2.8e-05	0.000205	CcSEcCtD
Cladribine—Chills—Doxorubicin—kidney cancer	2.79e-05	0.000204	CcSEcCtD
Cladribine—Arrhythmia—Doxorubicin—kidney cancer	2.78e-05	0.000203	CcSEcCtD
Cladribine—Dizziness—Paclitaxel—kidney cancer	2.76e-05	0.000202	CcSEcCtD
Cladribine—Alopecia—Doxorubicin—kidney cancer	2.75e-05	0.000201	CcSEcCtD
Cladribine—Mental disorder—Doxorubicin—kidney cancer	2.72e-05	0.000199	CcSEcCtD
Cladribine—Urticaria—Capecitabine—kidney cancer	2.72e-05	0.000199	CcSEcCtD
Cladribine—Abdominal pain—Capecitabine—kidney cancer	2.71e-05	0.000198	CcSEcCtD
Cladribine—Body temperature increased—Capecitabine—kidney cancer	2.71e-05	0.000198	CcSEcCtD
Cladribine—Erythema—Doxorubicin—kidney cancer	2.71e-05	0.000198	CcSEcCtD
Cladribine—Malnutrition—Doxorubicin—kidney cancer	2.71e-05	0.000198	CcSEcCtD
Cladribine—Flatulence—Doxorubicin—kidney cancer	2.67e-05	0.000195	CcSEcCtD
Cladribine—Vomiting—Paclitaxel—kidney cancer	2.65e-05	0.000194	CcSEcCtD
Cladribine—Rash—Paclitaxel—kidney cancer	2.63e-05	0.000192	CcSEcCtD
Cladribine—Dermatitis—Paclitaxel—kidney cancer	2.63e-05	0.000192	CcSEcCtD
Cladribine—Back pain—Doxorubicin—kidney cancer	2.62e-05	0.000191	CcSEcCtD
Cladribine—Headache—Paclitaxel—kidney cancer	2.61e-05	0.000191	CcSEcCtD
Cladribine—Hypersensitivity—Capecitabine—kidney cancer	2.52e-05	0.000185	CcSEcCtD
Cladribine—Ill-defined disorder—Doxorubicin—kidney cancer	2.51e-05	0.000184	CcSEcCtD
Cladribine—Anaemia—Doxorubicin—kidney cancer	2.5e-05	0.000183	CcSEcCtD
Cladribine—Nausea—Paclitaxel—kidney cancer	2.48e-05	0.000181	CcSEcCtD
Cladribine—Asthenia—Capecitabine—kidney cancer	2.46e-05	0.00018	CcSEcCtD
Cladribine—Malaise—Doxorubicin—kidney cancer	2.44e-05	0.000178	CcSEcCtD
Cladribine—Pruritus—Capecitabine—kidney cancer	2.42e-05	0.000177	CcSEcCtD
Cladribine—Cough—Doxorubicin—kidney cancer	2.36e-05	0.000173	CcSEcCtD
Cladribine—Diarrhoea—Capecitabine—kidney cancer	2.34e-05	0.000171	CcSEcCtD
Cladribine—Chest pain—Doxorubicin—kidney cancer	2.3e-05	0.000168	CcSEcCtD
Cladribine—Myalgia—Doxorubicin—kidney cancer	2.3e-05	0.000168	CcSEcCtD
Cladribine—Arthralgia—Doxorubicin—kidney cancer	2.3e-05	0.000168	CcSEcCtD
Cladribine—Anxiety—Doxorubicin—kidney cancer	2.3e-05	0.000168	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	2.29e-05	0.000167	CcSEcCtD
Cladribine—Discomfort—Doxorubicin—kidney cancer	2.28e-05	0.000166	CcSEcCtD
Cladribine—Dizziness—Capecitabine—kidney cancer	2.26e-05	0.000166	CcSEcCtD
Cladribine—Confusional state—Doxorubicin—kidney cancer	2.23e-05	0.000163	CcSEcCtD
Cladribine—Oedema—Doxorubicin—kidney cancer	2.21e-05	0.000161	CcSEcCtD
Cladribine—Infection—Doxorubicin—kidney cancer	2.19e-05	0.00016	CcSEcCtD
Cladribine—Vomiting—Capecitabine—kidney cancer	2.18e-05	0.000159	CcSEcCtD
Cladribine—Nervous system disorder—Doxorubicin—kidney cancer	2.17e-05	0.000158	CcSEcCtD
Cladribine—Thrombocytopenia—Doxorubicin—kidney cancer	2.16e-05	0.000158	CcSEcCtD
Cladribine—Rash—Capecitabine—kidney cancer	2.16e-05	0.000158	CcSEcCtD
Cladribine—Dermatitis—Capecitabine—kidney cancer	2.16e-05	0.000158	CcSEcCtD
Cladribine—Tachycardia—Doxorubicin—kidney cancer	2.15e-05	0.000158	CcSEcCtD
Cladribine—Headache—Capecitabine—kidney cancer	2.15e-05	0.000157	CcSEcCtD
Cladribine—Skin disorder—Doxorubicin—kidney cancer	2.14e-05	0.000157	CcSEcCtD
Cladribine—Hyperhidrosis—Doxorubicin—kidney cancer	2.13e-05	0.000156	CcSEcCtD
Cladribine—Anorexia—Doxorubicin—kidney cancer	2.1e-05	0.000154	CcSEcCtD
Cladribine—RRM1—Metabolism—SCARB1—kidney cancer	2.09e-05	0.000293	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PTGS1—kidney cancer	2.07e-05	0.00029	CbGpPWpGaD
Cladribine—Hypotension—Doxorubicin—kidney cancer	2.06e-05	0.000151	CcSEcCtD
Cladribine—POLE2—Cell Cycle—CCND1—kidney cancer	2.04e-05	0.000287	CbGpPWpGaD
Cladribine—Nausea—Capecitabine—kidney cancer	2.03e-05	0.000149	CcSEcCtD
Cladribine—NR5A1—Developmental Biology—VEGFA—kidney cancer	2.03e-05	0.000285	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PSMD7—kidney cancer	2.03e-05	0.000285	CbGpPWpGaD
Cladribine—Musculoskeletal discomfort—Doxorubicin—kidney cancer	2.01e-05	0.000147	CcSEcCtD
Cladribine—DCK—Metabolism—CRABP1—kidney cancer	2e-05	0.000281	CbGpPWpGaD
Cladribine—Insomnia—Doxorubicin—kidney cancer	2e-05	0.000146	CcSEcCtD
Cladribine—RRM2B—Metabolism—POMC—kidney cancer	2e-05	0.00028	CbGpPWpGaD
Cladribine—RRM2—Metabolism—ITPR2—kidney cancer	1.99e-05	0.00028	CbGpPWpGaD
Cladribine—NR5A1—Generic Transcription Pathway—MYC—kidney cancer	1.99e-05	0.000279	CbGpPWpGaD
Cladribine—Paraesthesia—Doxorubicin—kidney cancer	1.98e-05	0.000145	CcSEcCtD
Cladribine—Dyspnoea—Doxorubicin—kidney cancer	1.97e-05	0.000144	CcSEcCtD
Cladribine—Somnolence—Doxorubicin—kidney cancer	1.96e-05	0.000144	CcSEcCtD
Cladribine—POLA1—Cell Cycle—BRCA2—kidney cancer	1.96e-05	0.000275	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ACY1—kidney cancer	1.95e-05	0.000273	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CDKN2B—kidney cancer	1.94e-05	0.000273	CbGpPWpGaD
Cladribine—RRM1—Metabolism—BCHE—kidney cancer	1.92e-05	0.00027	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—MAPK3—kidney cancer	1.92e-05	0.00027	CbGpPWpGaD
Cladribine—Decreased appetite—Doxorubicin—kidney cancer	1.92e-05	0.00014	CcSEcCtD
Cladribine—Gastrointestinal disorder—Doxorubicin—kidney cancer	1.91e-05	0.000139	CcSEcCtD
Cladribine—Fatigue—Doxorubicin—kidney cancer	1.9e-05	0.000139	CcSEcCtD
Cladribine—RRM1—Metabolism—SLC5A5—kidney cancer	1.9e-05	0.000266	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—VEGFA—kidney cancer	1.89e-05	0.000265	CbGpPWpGaD
Cladribine—Constipation—Doxorubicin—kidney cancer	1.89e-05	0.000138	CcSEcCtD
Cladribine—Pain—Doxorubicin—kidney cancer	1.89e-05	0.000138	CcSEcCtD
Cladribine—POLE2—Cell Cycle, Mitotic—MAPK3—kidney cancer	1.89e-05	0.000265	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—BIRC5—kidney cancer	1.88e-05	0.000263	CbGpPWpGaD
Cladribine—DCK—Metabolism—ITPR2—kidney cancer	1.86e-05	0.000261	CbGpPWpGaD
Cladribine—RRM1—Metabolism—SLC2A1—kidney cancer	1.83e-05	0.000257	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—MYC—kidney cancer	1.83e-05	0.000257	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—MAPK1—kidney cancer	1.83e-05	0.000256	CbGpPWpGaD
Cladribine—Feeling abnormal—Doxorubicin—kidney cancer	1.82e-05	0.000133	CcSEcCtD
Cladribine—RRM2—Metabolism—GSTT1—kidney cancer	1.82e-05	0.000255	CbGpPWpGaD
Cladribine—RRM2—Metabolism—ACHE—kidney cancer	1.82e-05	0.000255	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—CDKN2A—kidney cancer	1.82e-05	0.000255	CbGpPWpGaD
Cladribine—Gastrointestinal pain—Doxorubicin—kidney cancer	1.81e-05	0.000132	CcSEcCtD
Cladribine—ABCG2—Metabolism—PDHB—kidney cancer	1.8e-05	0.000252	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—MAPK1—kidney cancer	1.79e-05	0.000252	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	1.79e-05	0.000251	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PDHB—kidney cancer	1.78e-05	0.000249	CbGpPWpGaD
Cladribine—Urticaria—Doxorubicin—kidney cancer	1.75e-05	0.000128	CcSEcCtD
Cladribine—Body temperature increased—Doxorubicin—kidney cancer	1.75e-05	0.000128	CcSEcCtD
Cladribine—Abdominal pain—Doxorubicin—kidney cancer	1.75e-05	0.000128	CcSEcCtD
Cladribine—POLE—Cell Cycle, Mitotic—CDKN2A—kidney cancer	1.74e-05	0.000245	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	1.74e-05	0.000244	CbGpPWpGaD
Cladribine—PNP—Metabolism—POMC—kidney cancer	1.73e-05	0.000243	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—KRAS—kidney cancer	1.73e-05	0.000242	CbGpPWpGaD
Cladribine—RRM2—Metabolism—SCARB1—kidney cancer	1.72e-05	0.000241	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PTGS1—kidney cancer	1.7e-05	0.000239	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	1.7e-05	0.000239	CbGpPWpGaD
Cladribine—DCK—Metabolism—ACHE—kidney cancer	1.7e-05	0.000238	CbGpPWpGaD
Cladribine—DCK—Metabolism—GSTT1—kidney cancer	1.7e-05	0.000238	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CCBL1—kidney cancer	1.69e-05	0.000237	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—MAPK3—kidney cancer	1.69e-05	0.000237	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—BIRC5—kidney cancer	1.68e-05	0.000235	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PSMD7—kidney cancer	1.67e-05	0.000234	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CCBL1—kidney cancer	1.67e-05	0.000234	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PDHB—kidney cancer	1.66e-05	0.000232	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—MYC—kidney cancer	1.64e-05	0.00023	CbGpPWpGaD
Cladribine—Hypersensitivity—Doxorubicin—kidney cancer	1.63e-05	0.000119	CcSEcCtD
Cladribine—POLE—Mitotic M-M/G1 phases—MAPK3—kidney cancer	1.63e-05	0.000228	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—CDKN2A—kidney cancer	1.62e-05	0.000228	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—CDKN1B—kidney cancer	1.61e-05	0.000226	CbGpPWpGaD
Cladribine—DCK—Metabolism—SCARB1—kidney cancer	1.61e-05	0.000226	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	1.61e-05	0.000226	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—MAPK1—kidney cancer	1.6e-05	0.000225	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—PTGS2—kidney cancer	1.59e-05	0.000223	CbGpPWpGaD
Cladribine—DCK—Metabolism—PTGS1—kidney cancer	1.59e-05	0.000223	CbGpPWpGaD
Cladribine—Asthenia—Doxorubicin—kidney cancer	1.58e-05	0.000116	CcSEcCtD
Cladribine—RRM2—Metabolism—BCHE—kidney cancer	1.58e-05	0.000222	CbGpPWpGaD
Cladribine—RRM2—Metabolism—SLC5A5—kidney cancer	1.56e-05	0.000219	CbGpPWpGaD
Cladribine—Pruritus—Doxorubicin—kidney cancer	1.56e-05	0.000114	CcSEcCtD
Cladribine—DCK—Metabolism—PSMD7—kidney cancer	1.56e-05	0.000219	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—CDKN2A—kidney cancer	1.56e-05	0.000219	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CCBL1—kidney cancer	1.56e-05	0.000218	CbGpPWpGaD
Cladribine—SLC22A2—Transmission across Chemical Synapses—BRAF—kidney cancer	1.55e-05	0.000217	CbGpPWpGaD
Cladribine—POLE—Mitotic M-M/G1 phases—MAPK1—kidney cancer	1.55e-05	0.000217	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—CDKN1B—kidney cancer	1.54e-05	0.000217	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—CCND1—kidney cancer	1.54e-05	0.000215	CbGpPWpGaD
Cladribine—RRM1—Metabolism—GSTP1—kidney cancer	1.53e-05	0.000215	CbGpPWpGaD
Cladribine—RRM2—Metabolism—SLC2A1—kidney cancer	1.51e-05	0.000212	CbGpPWpGaD
Cladribine—Diarrhoea—Doxorubicin—kidney cancer	1.51e-05	0.00011	CcSEcCtD
Cladribine—DCK—Metabolism—BCHE—kidney cancer	1.48e-05	0.000208	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	1.48e-05	0.000207	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—CCND1—kidney cancer	1.47e-05	0.000207	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PPAT—kidney cancer	1.46e-05	0.000205	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GLIPR1—kidney cancer	1.46e-05	0.000205	CbGpPWpGaD
Cladribine—DCK—Metabolism—SLC5A5—kidney cancer	1.46e-05	0.000205	CbGpPWpGaD
Cladribine—Dizziness—Doxorubicin—kidney cancer	1.46e-05	0.000107	CcSEcCtD
Cladribine—SLC22A2—Metabolism—GLIPR1—kidney cancer	1.45e-05	0.000203	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PPAT—kidney cancer	1.45e-05	0.000203	CbGpPWpGaD
Cladribine—RRM1—Metabolism—ABCB1—kidney cancer	1.45e-05	0.000203	CbGpPWpGaD
Cladribine—SLC22A1—Transmission across Chemical Synapses—BRAF—kidney cancer	1.44e-05	0.000203	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—CDKN1B—kidney cancer	1.44e-05	0.000202	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	1.43e-05	0.0002	CbGpPWpGaD
Cladribine—DCK—Metabolism—SLC2A1—kidney cancer	1.41e-05	0.000198	CbGpPWpGaD
Cladribine—RRM1—Metabolism—GSTM1—kidney cancer	1.41e-05	0.000197	CbGpPWpGaD
Cladribine—Vomiting—Doxorubicin—kidney cancer	1.4e-05	0.000103	CcSEcCtD
Cladribine—Rash—Doxorubicin—kidney cancer	1.39e-05	0.000102	CcSEcCtD
Cladribine—Dermatitis—Doxorubicin—kidney cancer	1.39e-05	0.000102	CcSEcCtD
Cladribine—RRM2B—Metabolism—PTEN—kidney cancer	1.39e-05	0.000195	CbGpPWpGaD
Cladribine—Headache—Doxorubicin—kidney cancer	1.38e-05	0.000101	CcSEcCtD
Cladribine—POLE—Cell Cycle—CDKN1B—kidney cancer	1.38e-05	0.000194	CbGpPWpGaD
Cladribine—PNP—Metabolism—PTGS2—kidney cancer	1.38e-05	0.000194	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—CCND1—kidney cancer	1.37e-05	0.000193	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—FH—kidney cancer	1.36e-05	0.000191	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—APRT—kidney cancer	1.36e-05	0.000191	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PPAT—kidney cancer	1.35e-05	0.000189	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GLIPR1—kidney cancer	1.35e-05	0.000189	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—TP53—kidney cancer	1.35e-05	0.000189	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—FH—kidney cancer	1.35e-05	0.000189	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—APRT—kidney cancer	1.35e-05	0.000189	CbGpPWpGaD
Cladribine—RRM1—Metabolism—CYP1A1—kidney cancer	1.33e-05	0.000187	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—CCND1—kidney cancer	1.32e-05	0.000185	CbGpPWpGaD
Cladribine—Nausea—Doxorubicin—kidney cancer	1.31e-05	9.59e-05	CcSEcCtD
Cladribine—SLC22A2—Transmission across Chemical Synapses—RAF1—kidney cancer	1.29e-05	0.000182	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GPC3—kidney cancer	1.28e-05	0.000179	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—MAPK3—kidney cancer	1.27e-05	0.000178	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GPC3—kidney cancer	1.27e-05	0.000178	CbGpPWpGaD
Cladribine—RRM2—Metabolism—GSTP1—kidney cancer	1.26e-05	0.000177	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—APRT—kidney cancer	1.25e-05	0.000176	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—FH—kidney cancer	1.25e-05	0.000176	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—SLC5A5—kidney cancer	1.25e-05	0.000175	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CA2—kidney cancer	1.24e-05	0.000175	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—CDKN2A—kidney cancer	1.24e-05	0.000174	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—SLC5A5—kidney cancer	1.24e-05	0.000173	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CA2—kidney cancer	1.23e-05	0.000173	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—MYC—kidney cancer	1.23e-05	0.000173	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—MAPK3—kidney cancer	1.22e-05	0.000171	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ALAD—kidney cancer	1.21e-05	0.00017	CbGpPWpGaD
Cladribine—SLC22A1—Transmission across Chemical Synapses—RAF1—kidney cancer	1.21e-05	0.000169	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—SLC2A1—kidney cancer	1.21e-05	0.000169	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—MAPK1—kidney cancer	1.2e-05	0.000169	CbGpPWpGaD
Cladribine—PNP—Metabolism—PTEN—kidney cancer	1.2e-05	0.000169	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ALAD—kidney cancer	1.2e-05	0.000168	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—SLC2A1—kidney cancer	1.19e-05	0.000167	CbGpPWpGaD
Cladribine—RRM2—Metabolism—ABCB1—kidney cancer	1.19e-05	0.000167	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—BRAF—kidney cancer	1.19e-05	0.000167	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ST3GAL2—kidney cancer	1.18e-05	0.000166	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—MYC—kidney cancer	1.18e-05	0.000166	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GPC3—kidney cancer	1.18e-05	0.000166	CbGpPWpGaD
Cladribine—DCK—Metabolism—GSTP1—kidney cancer	1.18e-05	0.000165	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ST3GAL2—kidney cancer	1.17e-05	0.000164	CbGpPWpGaD
Cladribine—POLA1—Mitotic M-M/G1 phases—MAPK3—kidney cancer	1.16e-05	0.000162	CbGpPWpGaD
Cladribine—RRM2—Metabolism—GSTM1—kidney cancer	1.16e-05	0.000162	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ALDH1A1—kidney cancer	1.16e-05	0.000162	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—MAPK1—kidney cancer	1.16e-05	0.000162	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—SLC5A5—kidney cancer	1.15e-05	0.000162	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CA2—kidney cancer	1.15e-05	0.000161	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ALDH1A1—kidney cancer	1.14e-05	0.000161	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—MAPK3—kidney cancer	1.13e-05	0.000159	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ALAD—kidney cancer	1.12e-05	0.000157	CbGpPWpGaD
Cladribine—DCK—Metabolism—ABCB1—kidney cancer	1.11e-05	0.000156	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—SLC2A1—kidney cancer	1.11e-05	0.000156	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CDKN2A—kidney cancer	1.11e-05	0.000156	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PGK1—kidney cancer	1.11e-05	0.000156	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—SLC5A3—kidney cancer	1.11e-05	0.000156	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—BRAF—kidney cancer	1.11e-05	0.000155	CbGpPWpGaD
Cladribine—POLA1—Mitotic M-M/G1 phases—MAPK1—kidney cancer	1.1e-05	0.000155	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—MYC—kidney cancer	1.1e-05	0.000154	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—CDKN1B—kidney cancer	1.1e-05	0.000154	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—SLC5A3—kidney cancer	1.1e-05	0.000154	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PGK1—kidney cancer	1.1e-05	0.000154	CbGpPWpGaD
Cladribine—RRM2—Metabolism—CYP1A1—kidney cancer	1.1e-05	0.000154	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ST3GAL2—kidney cancer	1.09e-05	0.000153	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—LDHB—kidney cancer	1.09e-05	0.000153	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—MAPK3—kidney cancer	1.09e-05	0.000152	CbGpPWpGaD
Cladribine—DCK—Metabolism—GSTM1—kidney cancer	1.08e-05	0.000152	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—MAPK1—kidney cancer	1.08e-05	0.000151	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—LDHB—kidney cancer	1.08e-05	0.000151	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ALDH1A1—kidney cancer	1.07e-05	0.00015	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—MYC—kidney cancer	1.06e-05	0.000148	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—CCND1—kidney cancer	1.05e-05	0.000147	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—MAPK1—kidney cancer	1.03e-05	0.000145	CbGpPWpGaD
Cladribine—DCK—Metabolism—CYP1A1—kidney cancer	1.03e-05	0.000144	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PGK1—kidney cancer	1.02e-05	0.000144	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—SLC5A3—kidney cancer	1.02e-05	0.000144	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—LDHB—kidney cancer	1e-05	0.000141	CbGpPWpGaD
Cladribine—RRM1—Metabolism—POMC—kidney cancer	9.94e-06	0.000139	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—RAF1—kidney cancer	9.92e-06	0.000139	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CDKN1B—kidney cancer	9.84e-06	0.000138	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—MAPK3—kidney cancer	9.83e-06	0.000138	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—PIK3CA—kidney cancer	9.79e-06	0.000137	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—MYC—kidney cancer	9.56e-06	0.000134	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—ABCB1—kidney cancer	9.52e-06	0.000134	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CA9—kidney cancer	9.43e-06	0.000132	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—ABCB1—kidney cancer	9.42e-06	0.000132	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CCND1—kidney cancer	9.39e-06	0.000132	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CA9—kidney cancer	9.33e-06	0.000131	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—RAF1—kidney cancer	9.24e-06	0.00013	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—TP53—kidney cancer	9.04e-06	0.000127	CbGpPWpGaD
Cladribine—SLC22A2—Transmission across Chemical Synapses—MAPK1—kidney cancer	8.88e-06	0.000125	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—ABCB1—kidney cancer	8.78e-06	0.000123	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CA9—kidney cancer	8.7e-06	0.000122	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—TP53—kidney cancer	8.68e-06	0.000122	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—MAPK3—kidney cancer	8.66e-06	0.000121	CbGpPWpGaD
Cladribine—PNP—Metabolism—PIK3CA—kidney cancer	8.49e-06	0.000119	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—MYC—kidney cancer	8.42e-06	0.000118	CbGpPWpGaD
Cladribine—SLC22A1—Transmission across Chemical Synapses—MAPK1—kidney cancer	8.27e-06	0.000116	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—MAPK1—kidney cancer	8.24e-06	0.000116	CbGpPWpGaD
Cladribine—RRM2—Metabolism—POMC—kidney cancer	8.18e-06	0.000115	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CRABP1—kidney cancer	8.02e-06	0.000112	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CRABP1—kidney cancer	7.94e-06	0.000111	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PTGS2—kidney cancer	7.93e-06	0.000111	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—MAPK3—kidney cancer	7.74e-06	0.000109	CbGpPWpGaD
Cladribine—DCK—Metabolism—POMC—kidney cancer	7.65e-06	0.000107	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—MYC—kidney cancer	7.53e-06	0.000106	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ITPR2—kidney cancer	7.45e-06	0.000105	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CRABP1—kidney cancer	7.4e-06	0.000104	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ITPR2—kidney cancer	7.38e-06	0.000103	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—MAPK1—kidney cancer	7.37e-06	0.000103	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PTEN—kidney cancer	6.91e-06	9.7e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ITPR2—kidney cancer	6.88e-06	9.65e-05	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—MAPK1—kidney cancer	6.8e-06	9.54e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ACHE—kidney cancer	6.8e-06	9.54e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GSTT1—kidney cancer	6.8e-06	9.54e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GSTT1—kidney cancer	6.73e-06	9.44e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ACHE—kidney cancer	6.73e-06	9.44e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PTGS2—kidney cancer	6.53e-06	9.16e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—SCARB1—kidney cancer	6.43e-06	9.03e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PTGS1—kidney cancer	6.37e-06	8.94e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—SCARB1—kidney cancer	6.37e-06	8.93e-05	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—MAPK1—kidney cancer	6.34e-06	8.89e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PTGS1—kidney cancer	6.3e-06	8.84e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GSTT1—kidney cancer	6.27e-06	8.8e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ACHE—kidney cancer	6.27e-06	8.8e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PSMD7—kidney cancer	6.25e-06	8.76e-05	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—TP53—kidney cancer	6.19e-06	8.68e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PSMD7—kidney cancer	6.18e-06	8.67e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—PTGS2—kidney cancer	6.1e-06	8.56e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—SCARB1—kidney cancer	5.94e-06	8.33e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—BCHE—kidney cancer	5.92e-06	8.31e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PTGS1—kidney cancer	5.88e-06	8.24e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—BCHE—kidney cancer	5.86e-06	8.22e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—SLC5A5—kidney cancer	5.85e-06	8.21e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—SLC5A5—kidney cancer	5.79e-06	8.12e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PSMD7—kidney cancer	5.76e-06	8.08e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PTEN—kidney cancer	5.69e-06	7.99e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—SLC2A1—kidney cancer	5.65e-06	7.93e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—SLC2A1—kidney cancer	5.59e-06	7.84e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—BCHE—kidney cancer	5.46e-06	7.66e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—SLC5A5—kidney cancer	5.4e-06	7.57e-05	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—RAF1—kidney cancer	5.39e-06	7.56e-05	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—RAF1—kidney cancer	5.33e-06	7.48e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—PTEN—kidney cancer	5.32e-06	7.46e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—SLC2A1—kidney cancer	5.21e-06	7.31e-05	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—RAF1—kidney cancer	4.97e-06	6.97e-05	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PIK3CA—kidney cancer	4.88e-06	6.84e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GSTP1—kidney cancer	4.71e-06	6.61e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GSTP1—kidney cancer	4.66e-06	6.54e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ABCB1—kidney cancer	4.46e-06	6.26e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ABCB1—kidney cancer	4.41e-06	6.19e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GSTP1—kidney cancer	4.35e-06	6.1e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GSTM1—kidney cancer	4.33e-06	6.07e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GSTM1—kidney cancer	4.29e-06	6.01e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ABCB1—kidney cancer	4.11e-06	5.77e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CYP1A1—kidney cancer	4.1e-06	5.76e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CYP1A1—kidney cancer	4.06e-06	5.7e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PIK3CA—kidney cancer	4.02e-06	5.63e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GSTM1—kidney cancer	3.99e-06	5.6e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CYP1A1—kidney cancer	3.79e-06	5.31e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—PIK3CA—kidney cancer	3.75e-06	5.26e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—POMC—kidney cancer	3.06e-06	4.29e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—POMC—kidney cancer	3.03e-06	4.25e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—POMC—kidney cancer	2.82e-06	3.96e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PTGS2—kidney cancer	2.44e-06	3.42e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PTGS2—kidney cancer	2.42e-06	3.39e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PTGS2—kidney cancer	2.25e-06	3.16e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PTEN—kidney cancer	2.13e-06	2.99e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PTEN—kidney cancer	2.11e-06	2.96e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PTEN—kidney cancer	1.96e-06	2.75e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PIK3CA—kidney cancer	1.5e-06	2.11e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PIK3CA—kidney cancer	1.49e-06	2.09e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PIK3CA—kidney cancer	1.39e-06	1.94e-05	CbGpPWpGaD
